Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05621291 · ClinicalTrials.gov registry record · NA
A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...
A NA study of Acute Lymphoblastic Leukemia and B-ALL, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 8
- Study locations
NCT05621291 is a NA study of Acute Lymphoblastic Leukemia and B-ALL that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 60 participants, below the 382-participant average among 131 other Acute Lymphoblastic Leukemia trials with a reported enrollment target (84% lower). The trial reports 8 study locations across 7 states.
The verdict
NCT05621291, a NA study of Acute Lymphoblastic Leukemia and B-ALL, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 8
- Study locations
Study Summary
Background: Chimeric antigen receptor T-cell (CART) therapy is a form of immunotherapy which can be used to treat people with relapsed B-ALL. For those who achieve remission after CART alone, it may cure up to 50% of people who receive this therapy. However, for people who relapse after CART, it can be hard to achieve remission again. In patients where CART fails, stem cell transplant (HCT) can be used to prevent relapse and achieve cure. But HCT can cause serious side effects. Better testing is needed to distinguish people who can be cured with CART alone from people who may also need to have HCT. Objective: To see if the use of a series of blood and bone marrow tests at regular intervals can help monitor for B-ALL relapse after CART therapy. Eligibility: People aged 1 to 25 years with B-ALL who have had CART therapy within the past 42 days. They must never have had a blood stem cell transplant; they must also have no measurable blood cancer cells. Design: Participants will visit the clinic every 2 weeks starting 42 days after they receive CART therapy. Each visit will be about the same amount of time as a regular clinic visit. about 8 hours. Participants will have blood drawn for testing on each visit. Bone marrow biopsy/aspirate will be done during 4 of the visits at routine timepoints after CART. A needle will be inserted to draw a sample of tissue from inside the bone in the hip. A small amount of blood and tissue will be tested with ClonoSEQ and to evaluate for normal B-cells side by side with the standard tests. The combined testing may help determine whether participants are eligible for HCT and/or at risk of relapse after CART. Participants will be in the study for 2 years.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST NGS testing
Study Locations (8)
Washington
- Seattle Children's, University of Washington - Seattle
- Fred Hutchinson Cancer Research Center - Seattle
California
- Children's Hospital of Los Angeles - Los Angeles
District of Columbia
- Children's National Medical Center - Washington D.C.
Georgia
- Children's Healthcare of Atlanta - Atlanta
Maryland
- National Institutes of Health Clinical Center - Bethesda
Massachusetts
- Dana-Farber/Boston Children s Hospital - Boston
Utah
- Huntsman Cancer Institute, University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-03-26 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05621291
The ClinicalTrials.gov registry entry for NCT05621291 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 382-participant average among 131 other Acute Lymphoblastic Leukemia trials with a reported enrollment target (84% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which NGS testing is the first listed.
NCT05621291 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Washington, California, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT05621291 about?
NCT05621291 is a clinical study titled "A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...". Background: Chimeric antigen receptor T-cell (CART) therapy is a form of immunotherapy which can be used to treat people with relapsed B-ALL. For those who achieve remission after CART alone, it may cure up to 50% of people who receive this therapy. However, for people who relapse after CART, it ca...
What is the current status of trial NCT05621291?
This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2026-03-26. Estimated completion is 2027-12-31.
What conditions does trial NCT05621291 study?
This clinical trial studies the following conditions: Acute Lymphoblastic Leukemia, B-ALL.
What interventions are being tested in trial NCT05621291?
The interventions under investigation include: NGS testing (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05621291?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05621291 being conducted?
This trial has 8 study locations across California, District of Columbia, Georgia, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mobile Health Intervention to Support Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia
RECRUITING · NA
-
MedSupport Intervention to Identify and Address Barriers to Pediatric Medication Adherence
RECRUITING · NA
-
A Bilingual Virtually-based Intervention (PEDALL) for the Prevention of Weight Gain in Childhood ALL Patients Considering Key Genetic and Sociodemographic Risk Factors
RECRUITING · NA
-
CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
RECRUITING · NA
-
A High Intensity Electronic Health Intervention for the Reduction of Learning Disparities in Childhood Cancer Survivors
ACTIVE NOT RECRUITING · NA
-
Feasibility Neurocognitive Outcome After Transplant
ACTIVE NOT RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.